Kagawa Toru, Takao Toshihiro, Horino Taro, Matsumoto Reiko, Inoue Kousuke, Morita Tatsuhito, Hashimoto Kozo
Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Nankoku, Japan.
Nephrology (Carlton). 2008 Jun;13(4):309-15. doi: 10.1111/j.1440-1797.2008.00918.x. Epub 2008 Mar 5.
We investigated the effect of angiotensin II (AII) type 1 (AT1) and angiotensin II type 2 (AT2) receptor blockers on tumour necrosis factor alpha (TNF-alpha)-induced cell damage in human renal proximal tubular epithelial cells (RPTEC).
The lactate dehydrogenase (LDH) and N-acetyl-beta-glucosaminidase (NAG) release into the medium after TNF-alpha treatment in RPTEC were determined using modified commercial procedures. In addition, the levels of caspase 3/7 activity in RPTEC were measured after TNF-alpha treatment with AlphaTau1 or AT2 receptor blockers. Finally we investigated the change of p22phox protein levels after TNF-alpha with AlphaTau1 or AT2 receptor blockers in RPTEC.
Tumour necrosis factor alpha (10(-8) mol/L) significantly increased LDH and NAG release into the medium from RPTEC. AlphaTau1 receptor blockers, olmesartan and valsartan (10(-9)-10(-6) mol/L) showed a significant reduction on TNF-alpha-induced LDH and NAG release in RPTEC. AT2 receptor blocker, PD123319 (10(-7)-10(-5) mol/L) also decreased TNF-alpha-induced LDH and NAG release in RPTEC. Blockade of both AlphaTau1 and AT2 receptor indicated additional reduction on TNF-alpha-induced LDH and NAG release. TNF-alpha (10(-8) mol/L) treatment showed small but significant increases of caspase 3/7 activity in RPTEC, and AT1 and AT2 receptor blockers (10(-8) mol/L) comparably decreased TNF-alpha-induced caspase 3/7 activity. Significant increases of p22phox protein levels were observed in TNF-alpha-treated group in RPTEC. However, only AlphaTau1 (10(-8) mol/L) but not AT2 (10(-5) mol/L) receptor blocker significantly decreased TNF-alpha-induced p22phox protein levels.
The present study demonstrates that TNF-alpha induces renal tubular cell damage in RPTEC and AT1/AT2 receptor blockers showed cytoprotective effects probably via at least partly different mechanism.
我们研究了1型血管紧张素II(AII)(AT1)受体阻滞剂和2型血管紧张素II(AT2)受体阻滞剂对肿瘤坏死因子α(TNF-α)诱导的人肾近端小管上皮细胞(RPTEC)损伤的影响。
采用改良的商业方法测定TNF-α处理后RPTEC中释放到培养基中的乳酸脱氢酶(LDH)和N-乙酰-β-氨基葡萄糖苷酶(NAG)。此外,在用AlphaTau1或AT2受体阻滞剂处理TNF-α后,测量RPTEC中caspase 3/7的活性水平。最后,我们研究了在RPTEC中用AlphaTau1或AT2受体阻滞剂处理TNF-α后p22phox蛋白水平的变化。
肿瘤坏死因子α(10⁻⁸mol/L)显著增加了RPTEC中释放到培养基中的LDH和NAG。AlphaTau1受体阻滞剂奥美沙坦和缬沙坦(10⁻⁹ - 10⁻⁶mol/L)显著降低了TNF-α诱导的RPTEC中LDH和NAG的释放。AT2受体阻滞剂PD123319(10⁻⁷ - 10⁻⁵mol/L)也降低了TNF-α诱导的RPTEC中LDH和NAG的释放。同时阻断AlphaTau1和AT2受体可进一步降低TNF-α诱导的LDH和NAG释放。TNF-α(10⁻⁸mol/L)处理使RPTEC中caspase 3/7活性有小幅但显著的增加,而AT1和AT2受体阻滞剂(10⁻⁸mol/L)可同等程度地降低TNF-α诱导的caspase 3/7活性。在TNF-α处理组的RPTEC中观察到p22phox蛋白水平显著升高。然而,只有AlphaTau1(10⁻⁸mol/L)而不是AT2(10⁻⁵mol/L)受体阻滞剂能显著降低TNF-α诱导的p22phox蛋白水平。
本研究表明TNF-α可诱导RPTEC中的肾小管细胞损伤,AT1/AT2受体阻滞剂可能通过至少部分不同的机制发挥细胞保护作用。